[{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Instil Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SYN-2510","moa":"PD-L1\/VEGF","graph1":"Technology","graph2":"Phase I\/II","graph3":"ImmuneOnco","amount2":2.0499999999999998,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"ImmuneOnco \/ Instil Bio","highestDevelopmentStatusID":"14","companyTruncated":"ImmuneOnco \/ Instil Bio"}]

Find Clinical Drug Pipeline Developments & Deals by ImmuneOnco

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Instil is the in-licensing agreement with ImmuneOnc for ex-China development and commercial rights of ImmueOnco’s PD-L1xVEGF bispecific antibody, IMM2510 for the treating advanced solid tumors.

                          Brand Name : IMM2510

                          Molecule Type : Large molecule

                          Upfront Cash : $50.0 million

                          August 01, 2024

                          Lead Product(s) : SYN-2510

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Instil Bio

                          Deal Size : $2,050.0 million

                          Deal Type : Licensing Agreement

                          blank